this is a broken record, April last year the CEO needed $30m to...

First 38 Last

Share
Profile

Follow
aidoaido

1,366 Posts.

43

14/08/15

12:37

Post #: 15808005
Share

Originally posted by amcfutures ↑

As far as we ascertain the technology has great potential across a wide range of diseases. Based on the earlier in utero (cell injection) and in vivo (animal studies) we can be reasonably certain that it is safe as Phase 1 will demonstrate.

Phase 2 has made a promising start since even at low doses there were signs of reduction in the viral load. However, to my knowledge we haven't yet established what the therapeutic dose is and certainly no idea of whether or not such would mean a cure or remission.

Based on 'typical' costs we can expect to spend about $30m to complete Phase 2. By the end of this quarter we will have about $18m cash available.

The bottomline is we need to raise more capital.

An IPO offers several advantages over a direct CR. In particular. it provides much wider exposure and allow more opportunity for a greater selection of, and incentive for, analysts to review and keep their possibly wide investor base abreast of progress.

In the global market perception (and in reality) BNTC remains a spec share albeit with excellent potential and if we can pull off the latest and hopefully the last edition of the IPO offer management will have done well.

And, in particular we should have sufficient funds to complete Phase 2 which like it or not has to be our prime focus.

Expand

this is a broken record,
April last year the CEO needed $30m to complete phase 2...

"The $31.5 million placement will allow Benitec to
complete Phase IIb trials in HCV, while also delivering
value through other clinical programs."
then successfully raised the $31.5m
now we need $30m again, WTF.

BLT Price at posting: 73.0¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

VUL

Vulcan appoints investment bank and M&A veteran to board

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

There are more pages in this discussion • 2 more messages in this thread...

First 38 Last

Add BLT (ASX) to my watchlist

this is a broken record, April last year the CEO needed $30m to...

Top Stories

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Vulcan appoints investment bank and M&A veteran to board

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Utah authorities sign off on Anson's lithium extraction plans at Green River

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Featured News